Open Access
| Numéro |
Med Sci (Paris)
Volume 40, Numéro 8-9, Août-Septembre 2024
|
|
|---|---|---|
| Page(s) | 613 - 615 | |
| Section | Nouvelles | |
| DOI | https://doi.org/10.1051/medsci/2024088 | |
| Publié en ligne | 20 septembre 2024 | |
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015 ; 372 : 320–30. [CrossRef] [PubMed] [Google Scholar]
- Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet Lond Engl 2016 ; 387 : 1540–50. [CrossRef] [Google Scholar]
- Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with Pembrolizumab in patients with classical Hodgkin lymphoma after Brentuximab Vedotin failure. J Clin Oncol 2016 ; 34 : 3733–9. [CrossRef] [PubMed] [Google Scholar]
- Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018 ; 359 : 1350–5. [Google Scholar]
- Arlauckas SP, Garris CS, Kohler RH, et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 2017 ; 9 : eaal3604. [CrossRef] [PubMed] [Google Scholar]
- Oh SA, Wu D-C, Cheung J, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer 2020 ; 1 : 681–91. [CrossRef] [PubMed] [Google Scholar]
- Sade-Feldman M, Yizhak K, Bjorgaard SL, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 2018 ; 175 : 998–1013.e20. [CrossRef] [PubMed] [Google Scholar]
- Siddiqui I, Schaeuble K, Chennupati V, et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 2019 ; 50 : 195–211.e10. [CrossRef] [PubMed] [Google Scholar]
- Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic immunity is required for effective cancer immunotherapy. Cell 2017 ; 168 : 487–502.e15. [CrossRef] [PubMed] [Google Scholar]
- Wu TD, Madireddi S, de Almeida PE, et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 2020 ; 579 : 274–8. [CrossRef] [PubMed] [Google Scholar]
- Ruggiu M, Guérin MV, Corre B, et al. Anti-PD-1 therapy triggers Tfh cell-dependent IL-4 release to boosT CD8 T cell responses in tumor-draining lymph nodes. J Exp Med 2024 ; 221 : e20232104. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.